Endothelial cells lining new blood vessels that develop during inflammatory disorders or cancers act as doors that either allow or block access to the tumor or inflamed organ. Recent data show that these endothelial cells in cancer tissues and inflamed tissues of lupus patients overexpress CD95L, the biological role of which is a subject of debate. The receptor CD95 (also named Fas or apoptosis antigen 1) belongs to the tumor necrosis factor (TNF) receptor superfamily. Its cognate ligand, CD95L, is implicated in immune homeostasis and immune surveillance. Because mutations of this receptor or its ligand lead to autoimmune disorders such as systemic lupus erythematosus (SLE) and cancers, CD95 and CD95L were initially thought to play a role in immune homeostasis and tumor elimination via apoptotic signaling pathways. However, recent data reveal that CD95 also evokes non-apoptotic signals, promotes inflammation, and contributes to carcinogenesis; therefore, it is difficult to dissect its apoptotic effects from its non-apoptotic effects during pathogenesis of disease. CD95L is cleaved by metalloproteases and so exists in two different forms: a transmembrane form and a soluble ligand (s-CD95L). We recently observed that the soluble ligand is overexpressed in serum from patients with triple-negative breast cancer or SLE, in whom it contributes to disease severity by activating non-apoptotic signaling pathways and promoting either metastatic dissemination or accumulation of certain T cell subsets in damaged organs. Here, we discuss the roles of CD95 in modulating immune functions via induction of mainly non-apoptotic signaling pathways.

Author Info: (1) Centre Eugne Marquis, Rennes, France. Equipe LabellisŽe Ligue Contre Le Cancer, INSERM U1242 COSS Institut National de la SantŽ et de la Recherche MŽdical, Rennes, France. Uni

Author Info: (1) Centre Eugne Marquis, Rennes, France. Equipe LabellisŽe Ligue Contre Le Cancer, INSERM U1242 COSS Institut National de la SantŽ et de la Recherche MŽdical, Rennes, France. UniversitŽ de Rennes-1, Rennes, France. (2) Centre Eugne Marquis, Rennes, France. Equipe LabellisŽe Ligue Contre Le Cancer, INSERM U1242 COSS Institut National de la SantŽ et de la Recherche MŽdical, Rennes, France. UniversitŽ de Rennes-1, Rennes, France. (3) Centre Hospitalier Universitaire (CHU) de Bordeaux, UniversitŽ de Bordeaux, Bordeaux, France. UMR CNRS 5164, Bordeaux, France. (4) Centre Eugne Marquis, Rennes, France. Equipe LabellisŽe Ligue Contre Le Cancer, INSERM U1242 COSS Institut National de la SantŽ et de la Recherche MŽdical, Rennes, France. UniversitŽ de Rennes-1, Rennes, France.